Thrombosis in pregnancy

Current Opinion in Hematology

Volumn 4, Issue 5, 1997, Pages 335-343

  Bates, Shannon M ^a   Ginsberg, Jeffrey S ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; EMBRYO; EMBRYOPATHY; FEMALE; FETUS; FETUS OUTCOME; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

EID: 0030847633     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704050-00007     Document Type: Review

References (96)

1. Bergqvist A, Bergqvist D, Hallbook T: Thrombosis during pregnancy: a prospective study. Acta Obstet Gynecol Scand 1983, 62:443-448.
2. Rutherford S, Montoro M, McGehee W, Strong T: Thromboembolic disease associated with pregnancy: an 11 year review [abstract]. Am J Obstet Gynecol 1991, 164(suppl):286.
3. Kierkegaard A: Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand 1983, 62:239-243.
4. Sachs BP, Brown DA, Driscoll SG, Schulman F, Acker D, Ransil BJ: Maternal mortality in Massachusetts: trends and prevention. N Engl J Med 1987, 316:667-672.
5. Atrash HK, Koonin LM, Lawson HW, Franks AL, Smith JC: Maternal mortality in the United States: 1979-1986. Obstet Gynecol 1990, 76:1055-1060.
6. Hogberg U, Innala E, Sandstrom A: Maternal mortality In Sweden. Obstet Gynecol 1994, 84:240-244.
7. Tengborn L, Bergqvist D, Matzch T, Bergqvist A, Hedner U: Recurrent thromboembolism in pregnancy and puerperium: is there a need for thromboprophylaxis? Am J Obstet Gynecol 1989, 160:90-94.
8. Ginsberg JS, Brill-Edwards P, Burrows RF, Bona R, Prandoni P, Buller HR, Lensing A: Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992, 67:519-520.
9. Ikard RW, Ueland K, Foise R: Lower limb venous dynamics in pregnant women. Surg Gynecol Obstet 1971, 132:483-488.
10. Kerr MG, Scott DB, Samuel E: Studies of the inferior vena cava In late pregnancy. Br Med J 1964, 1:532-533.
11. Rutherford SE, Phelan JP: Thromboembolic disease in pregnancy. Clin Perinatal 1986, 13:719-739.
12. Stirling Y, Woolf L, North WRS, Seghatchian MJ, Meade TW: Hemostasis in normal pregnancy. Thromb Haemost 1984, 52:176-182.
13. Woodhams BJ, Candotti G, Shaw R, Kernoff PB: Changes in coagulation and fibrinolysis during pregnancy: evidence of activation of coagulation preceding spontaneous abortion. Thromb Res 1989, 55:99-107.
14. Weiner CP, Kwaan H, Hauck WW, Duboe FJ, Paul M, Wallemark CB: Fibrin generation In normal pregnancy. Obstet Gynecol 1984, 64:46-48.
15. Wright JG, Cooper P, Astedt B, Lecander T, Wilde JT, Preston FE, Greaves M: Fibrinolysis during normal human pregnancy: complex interrelationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 1988, 69:253-258.
16. Bremme K, Ostlund E, Almqvist I, Heinonen K, Blomback M: Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol 1992, 80:132-137.
17. Kruithof EK, Tran-Thang C, Gudinchet A, Hauer ZS, Nicologo, G, Genton C, Welti H, Bachman F: Fibrinolysis In pregnancy: a study of plasminogen activator inhibitors. Blood 1987, 69:460-466.
18. Gonzalez R, Alberca I, Vicente V: Protein C levels in late pregnancy, postpartum, and in women on oral contraceptives. Thromb Res 1985, 39:637-640.
19. Comp PC, Thurnau GR, Welsh J, Esman C: Functional and immunolgic protein S levels are decreased during pregnancy. Blood 1986, 68:881-885.
20. Gjonnaess H, Fagerhol MK: Studies on coagulation and fibrinolysis in pregnancy. Acta Obstet Gynecol Scand 1975, 54:363-367.
21. Conrad J, Horellou MH, Van Dredan P, Lecompte T, Samama M: Thrombosis and pregnancy in congenital deficiencies of AT III, protein C, or protein S: study of 78 women. Thromb Haemost 1990, 63:319-320.
22. De Stafano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM: Thrombosis during pregnancy and surgery In patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994, 71:799-800.
23. Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994, 330:517-522.
24. Griffin JR, Evatt B, Wideman C, Fernandez JA: Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993, 82:1989-1993.
25. Cadroy Y, Sie P, Bonue B: Frequency of a defective response to activated protein C In patients with a history of venous thrombosis. Blood 1994, 83:2008-2009.
26. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993, 342:1503-1506.
27. Bertina RM, Koeleman BPD, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden P, Reitsam PH: Mutation In blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
28. Dahlback B: Physiologic anticoagulation: inherited resistance to activated protein C and venous thromboembolism. J Clin Invest 1994, 94:923-927.
29. Dahlback B: Resistance to activated protein C, the Arg 506 to Gln mutation in the factor V gene and venous thrombosis: functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995, 73:739-742.
30. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CRM: Development of resistance to activated protein C during pregnancy. Br J Haematol 1995, 90:725-727.
31. Jorquerow I, Montoro JM, Fernandez MA, Aznar JA, Aznar J: Modified test for activated protein resistance. Lancet 1994, 344:1162-1163.
32. Trossaert M, Conrad J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA: Modified ARC resistance assay for patients on oral anticoagulants. Lancet 1994, 344:1709.
33. Tosetto A, Rodeghiero F: Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995, 73:732-733.
34. Cadroy Y, Sie P, Alhenc-Geles M, Aiach M: Evaluation of APC resistance In the plasma of patients with O506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995, 73:734-735.
35. Cumming AM, Tait RD, Fildes S, Hay CPM: Diagnosis of APC resistance during pregnancy. Br J Haematol 1996, 92:1026-1027. Predilution of test plasma in factor V-deficient plasma allows accurate diagnosis of APCR by functional assay during pregnancy.
36. Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstein BM, Goldhaber SZ: Pulmonary embolism and deep venous thrombosis during pregnancy on oral contraceptive use: prevalence of factor V Leiden. Am Heart J 1996, 131:1145-1148.
37. Rai R, Regan L, Hadley E, Dave M, Cohen H: Second trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996, 92:489-490.
38. Barnes RW, Wu KK, Hoak JC: Fallibility of clinical diagnosis of venous thrombosis. JAMA 1975, 234:605-607.
39. Ginsberg JS, Hirsh J, Rainbox AJ, Coates G: Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 1989, 61:189-196.
40. Hull RD, Hirsh J, Sackett DL, Taylor DW, Carter C, Turpie AG, Powers P, Gent M: Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. Circulation 1981, 64:622-625.
41. Hull RD, Raskob GE, Leclerc JR, Jay RM, Hirsh J: The diagnosis of clinically suspected venous thrombosis. Clin Chest Med 1984, 5:439-456.
42. Hull RD, Raskob GE, Carter CJ: Serial impedance plethysmography in pregnant patients with clinically suspected deep vein thrombosis. Ann Intern Med 1990, 112:663-667.
43. Clarke-Pearson DL, Jelovsek FR: Alterations of occlusive cuff impedance plethysmography results in the obstetric patient Surgery 1981, 89:594-598.
44. White RH, McGahan JP, Daschback MM, Hartling RP: Diagnosis of deep vein thrombosis using duplex ultrasound. Ann Intern Med 1989, 111:297-304.
45. Lensing AWA, Prandoni P, Brandjes D, Huisman PM, Vigo M, Tomasella G, Krekt J, ten Cate CW, Huisman MV, Buller HR: Detection of deep vein thrombosis by real time B-mode ultrasonography. N Engl J Med 1989, 320:342-345.
46. Cronan JJ, Dorfman GS, Scola FM, Scheppes B, Alexander J: Deep vein thrombosis: ultrasound assessment during vein compression. Raodiology 1987, 162:191-194.
47. Lensing AWA, Levi MM, Buller H, Prandoni P, Vigo M, Agnelli G, Lupatelli L, Huisman MV, ten Cate JW: Diagnosis of deep vein thrombosis using an objective doppler method. Ann Intern Med 1990, 113:9-13.
48. Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, Coates G, Gill GJ, Turpie AGG, Doyle DJ, et al.: Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983, 98:891-899.
49. Hull RD, Hirsh J, Carter CJ, Raskob GE, Gill GH, Jay RM, Leclerc JR, David M, Coates G: Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985, 88:819-828.
50. PIOPED Investigators: Value of the ventilation-perfusion lung scan in acute pulmonary embolism: results of the prospective investigation of pulmonary embolism diagnosis (PIOPEO). JAMA 1990, 263:2753-2759.
51. Flessa HC, Kapstrom AB, Glueck HI, Will JJ: Placental transport of heparin. Am J Obstet Gynecol 1965, 93:570-573.
52. Hall JG, Pauli RM, Wilson KM: Maternal and fetal sequelae of anticoagulants during pregnancy. Am J Med 1980, 68:122-140.
53. Ginsberg JS, Hirsh J, Turner DC, Levine M, Burrows R: Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989, 61:197-203.
54. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R: Heparin therapy during pregnancy: risks to the fetus and mother. Arch Intern Med 1989, 149:2233-2236.
55. Ojukwu C, Jenkinson SD, Obeid D: Deep vein thrombosis In pregnancy and heparin hypersensitivity. Br J Obstet Gynaecol 1996, 103:934-936.
56. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Bent M, Kelton JG: Heparin-induced thrombocytopenia In patients treated with low-molecular-weight heparin. N Engl J Med 1995, 332:1330-1335.
57. Rhodes GR, Dixon RH, Silver D: Heparin-induced thrombocytopenia: eight cases with thrombotic complications. Ann Surg 1977, 186:752-756.
58. Griffith GC, Nichols G, Asher JD, Flahagan B: Heparin osteoporosis. JAMA 1965, 193:85-94.
59. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards, Burrows R, Coates G, Webber C: Heparin effect on bone density. Thromb Haemost 1990, 64:286-289.
60. Dahlman TC: Osteoporotic fractures and recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993, 168:1265-1270.
61. Dahlman TC, Lindvall N, Hellgren M: Osteopenia in pregnancy during long-term heparin treatment: a radiological study post-partum. Br J Obstet Gynecol 1990, 97:221-228.
62. Douketis JD, Ginsberg JS, Burrows RF, Duku EK, Webber CE, Brill Edwards P: The effects of long-term heparin therapy during pregnancy on bone density: a prospective matched cohort study. Thromb Haemost 1996, 75:254-257. This prospective matched cohort study concluded that long-term heparin therapy is associated with a significant reduction in bone density, although fractures are uncommon. No significant correlation between lumbar bone density and the dose or duration of heparin was shown.
63. Hiu SL, Slemenda CS, Jonston CC Jr: Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1975, 56:311-318.
64. Riggs BL, Melton LJ III: Involutional osteoporosis. N Engl J Med 1986, 314:1676-1696.
65. Zimran A, Shilo S, Fisher D, Bab I: Histomorphometric evaluation of reversible heparin-induced osteoporosis in pregnancy. Arch Intern Med 1986, 146:386-388.
66. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, el al.: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996, 334:682-687. This randomized trial concluded that LMWH can be used safely and effectively to treat nonpregnant patients with proximal DVT at home.
67. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, et al.: A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996, 334:677-681. In nonpregnant patients with proximal vein thrombosis, treatment with LMWH at home is effective and safe.
68. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E: Low molecular weight heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992, 340:152-156.
69. Forestier F, Daffos F, Capella-Pavlovsky M: Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984, 34:557-560.
70. Omri A, Dalaloye JF, Andersen H, Bachmann F: Low molecular weight heparin NOVO (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989, 61:55-56.
71. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliot CG, Lerner RG, Hall J, Sparling T, Norton J, et al.: Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992, 326:975-982.
72. Hirsh J, Levine MM: Low molecular weight heparin. Blood 1992, 79:1-17.
73. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C: Comparison of subcutaneous unfractionated heparin with low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994, 71:7-11.
74. Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E: Low molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996, 87:380-383.
75. Iturbe-Alessio I, Fonseca MC, Mutchinik O, Santos MA, Zajarias A, Salazar E: Risks of anticoagulant therapy In pregnant women with artificial heart valves. N Engl J Med 1986, 315:1390-1393.
76. Hirsh J, Cade JF, Gallus AS: Fetal effects of Coumadin administered during pregnancy. Blood 1970, 36:623-627.
77. Hirsh J, Hoak J: Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Circulation 1996, 93:2212-2245. A complete overview of venous thromboembolism from the Council on Thrombosis of the American Heart Association.
78. Orme ML, Lewis PJ, de Swiet M, Serlin MJ, Sibeon R, Baty JD, Breckenridge AM: May mothers given warfarin breast-feed their infants? Br Med J 1977, 1:1564-1565.
79. McKenna R, Cole ER, Vasan U: Is warfarin sodium contraindicated in lactatlng mothers? J Pediatr 1983, 103:325-327.
80. Fagner B, Ahlgren M, Astedt B: Acute massive pulmonary embolism treated with streptokinase during labor and the early puerperium. Acts Obstet Gynecol Scand 1990, 69:659-662.
81. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D: Heparin for 5 days as compared with 10 days In the Initial treatment of proximal venous thrombosis. N Engl J Med 1990, 332:1260-1264.
82. Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J: The relation between the activated partial thromboplastin time response and recurrence In patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996, 157:1677-1781.
83. Ginsberg JS, Hirsh J: Use of antithrombotic agents during pregnancy. Chest 1995, 108(suppl):305S-311S.
84. Anderson DR, Ginsberg JS, Burrows R, Brill-Edwards P: Subcutaneous heparin therapy during pregnancy: a need for concern at the time of delivery. Thromb Haemost 1991, 65:248-250.
85. Demers C, Ginsberg JS: Deep vein thrombosis and pulmonary embolism In pregnancy. Clin Chest Med 1992, 13:645-656.
86. Badaracco MA, Vessey M: Recurrent venous thromboembolic disease and the use of oral contraceptives. Be Med J 1974, 1:215-217.
87. de Swiet M, Floyd E, Letsky E: Low risk of recurrent thromboemblism in pregnancy. Br J Hosp Med 1987, 38:264.
88. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996, 125:1-7.
89. Levine MN, Hirsh J, Gent M, Turpei AG, Weitz J, Ginsberg J, Geerts W, Leclerc J, Neemeh J, Powers P, Piovella F: Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995, 74:606-611.
90. Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task: Guidelines on the presentation, Investigation, and management of thrombosis associated with pregnancy. J Clin Pathol 1993, 46:97-103.
91. Colvin BT, Barrowoliff TW: The British Society for Haematology guidelines on the use and monitoring of heparin, 1992: second revision. J Clin Pathol 1993, 45:97-103.
92. Feinstein D: Lupus anticoagulant, anticardiolipin antibodies, fetal loss, and systemic lupus erythematosus. Blood 1992, 80:859-862.
93. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV: A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996, 14:131-136.
94. Petri M: Systemic lupus erythematosus and pregnancy. Rheum Dis Clin North Am 1994, 20:87-118.
95. Cowchock FS, Reece EA, Balaban D, Branch DW, Rouffe L: Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment Am J Obstet Gynecol 1992, 166:1318-1323.
96. Rai RS, Cohen H, Dave M, Regan L: Randomized controlled trial of aspirin and aspirin plus heparin In pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997, 314:253-257. This randomized trial shows that the combination of aspirin and heparin is superior to aspirin alone in the treatment of pregnant women with a history of recurrent miscarriages in association with antiphospholipid antibodies.